




Albert Einstein College of Medicine

Montefiore

EINSTEIN'S INSTITUTE FOR AGING RESEARCH



*Staying healthy as we get older!*

Nir Barzilai, M.D.

Professor of Medicine and Genetics

Director: Institute for Aging Research

PI: The E-Nathan Shock Center

The E-Glenn Center for the  
Biology of Human Aging

- **Mechanisms of Co-Development of Cancer and Cardiovascular Disease in an Aging Population**

## **The Geroscience View:**

**Age-related changes in key pathways that underlie both cancer and heart disease**

# Conflicts

Founder and on the Board of:



Founder and Medical/ Scientific Consultant

life

*Biosciences*

**No conflict in this talk**


# Promise and challenges for Geroscience

---

- **Introduction to geroscience:**
- **Hallmarks of aging**
- **Gerotherapeutics (TAME)**
- **The immediate future of gerotherapeutics**

# Aging itself is the strongest risk factor for all age related diseases


(The Milbank Quarterly, Vol. 80, No. 1, 2002 from 1997 U.S. Vital Statistics)




*Genetics and environment of the individual determine which disease occurs first*

**Can we do something about aging?**

# Geroscience: Key to targeting aging



- **Healthy** lifespan has been extended in numerous animal models.
- Relevant drugs have been used in humans. (**Metformin, Rapamycin....**)



**Can we do something about it?**

# Metformin Attenuates Biological Hallmarks of Aging


Its been used for 70 years and is safe!!!

It was used to prevent flu and malaria

Its generic and cheap

Metformin in clinical studies  
Prevented, T2DM, CVD, AD/MCI  
And mortality (Cancer)

TAME will show it targets aging






# Substantial effects of metformin on health-span in humans:

- **Intervention in non-type 2 diabetes mellitus (T2DM):** Metformin delays T2DM (DPP).
- **Intervention:** Metformin delays CVD (UKPDS) in T2DM.
- **Association:** Metformin is associated with less cancer in patients with T2DM.
- Metformin may delay cognitive decline and AD, even in non-T2DM.
- **Phase 4:** lower mortality in patients with T2DM on metformin compared with non-diabetics.

Metformin is a **tool** to target aging

# Metformin decreases mortality in T2DM and in non-diabetics



# TAME study design:

**Age 65-80 AND  
Gait speed 0.4-1 m/sec OR Age-related disease (CVD, cancer, MCI)**

Inclusion  
Criteria

n = 3000

Double blind placebo-controlled trial

**(Clinical) Time to incidence of any major age-related disease:  
MI, stroke, cancer\*, CHF, MCI/dementia, or death. FDA**

Primary  
Outcome

**(Biological) Change in metformin levels and biomarkers of  
aging and age-related diseases NIA.** To provide convergent evidence  
of broad age-related effects while establishing a resource for innovation and  
discovery of emerging biomarkers.

# If we could do more TAME-like studies....

## Geroscience-guided repurposing of FDA-approved drugs for aging

\* Kulkarni A, \*Aleksic S, Berger D, Kuchel G, Sierra F and Barzilai N

Gerotherapeutic (lifespan)	Hallmarks of aging	Preclinical healthspan	Preclinical lifespan	Human healthspan	Human mortality	Score (out of 12)
SGLT-2 inhibitors	2	2	2	3	3	12
Metformin	2	2	1	3	1	9
Rapamycin/rapalogues	2	2	2	3	0 (not assessed)	9
Acarbose	2	2	2	3	0 (not assessed)	9
ACEi/ARB	2	2	1	3	0	8
Dasatinib + (quercetin)	2	2	1	1	0 (not assessed)	6
Aspirin	2	2	2	0	0	6
Methylene blue	2	2	2	0 (not assessed)	0 (not assessed)	6
N-acetyl cysteine	0	2	2	0	0	4

### Preclinical points


Hallmarks  $\geq 3$ : 2,  $< 3$ : 1  
 Healthspan increase: 2  
 Lifespan ITP: 2, non-ITP: 1

### Human points


Healthspan RCT: 3, observational/open single arm: 1  
 Mortality RCT: 3, observational: 1

Canagliflozin extends lifespan in genetically heterogeneous male but not female mice (Miller RA, JCI insight 10-20)

Dapagliflozin in patients with CKD (Heerspink et al, NEJM October 8 2020)




**A Primary Composite Outcome**



No. at Risk

Placebo	2152	1993	1936	1858	1791	1664	1232	774	270
Dapagliflozin	2152	2001	1955	1898	1841	1701	1288	831	309


**B Renal-Specific Composite Outcome**



No. at Risk

Placebo	2152	1993	1936	1858	1791	1664	1232	774	270
Dapagliflozin	2152	2001	1955	1898	1841	1701	1288	831	309


**C Composite of Death from Cardiovascular Causes or Hospitalization for Heart Failure**



No. at Risk

Placebo	2152	2023	1989	1957	1927	1853	1451	976	360
Dapagliflozin	2152	2035	2021	2003	1975	1895	1502	1003	384

**D Death from Any Cause**



No. at Risk

Placebo	2152	2035	2018	1993	1972	1902	1502	1009	379
Dapagliflozin	2152	2039	2029	2017	1998	1925	1531	1028	398


# Summary and challenges:

---

- **Geroscience: Treat aging and prevent cancer, CVD and much more!!!!**
- **Hallmarks of aging can be targeted and aging can be delayed**
- **Gerotherapeutics will demonstrate to the FDA that aging (age related diseases) is/are preventable**
- **More drugs for immediate future of gerotherapeutics**



# Challenges to translate our advance in understanding aging to humans?




**If diseases of aging are not recognized as preventable conditions:**


- 1) Healthcare provider would not pay for their clients.
- 2) Pharmaceuticals will not develop other, better and combination of drugs.




# Intervention Testing Program (NIA)



**NDGA**  
(Nordihydroguaiaretic acid)




**Aspirin**




**Acarbose**


Age (Days)



**17- $\alpha$  estradiol**



**Rapamycin**





**Rapamycin+  
metformin**



# Metformin Attenuates Biological Hallmarks of Aging

Kulkarni et al Cell Met



Biological Hallmarks of Aging

**Metformin extends lifespan and health span in animals. (683 papers in pubmed)**

# Blastocytes erase aging!



- Not only aging!
- A major foundation is coming

